Related Experiment Video
Updated: Aug 7, 2026

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
Published on: June 5, 2015
[Immunoglobulin therapy of neuromuscular diseases]
1Neurologische Universitätsklinik Heidelberg.
Abstract:
High-dose intravenous immunoglobulin (IVIG) is effective in myasthenia gravis (MG), Guillain-Barré syndrome (GBS), and chronic inflammatory polyneuropathy (CIDP). The effect is equivalent to plasmapheresis (PE), and in GBS perhaps superior. IVIG may be effective, even if PE or corticosteroids have been ineffective -- and vice versa. IVIG may well become the therapy of first choice in MG, GBS, and CIDP as it is easily administered, there are no serious side-effects and there exists no risk of virus transmission. Future studies will show if a combination of PE and IVIG is superior to either of the two treatment schedules alone.
More Related Videos
Related Concept Videos
Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Skeletal Muscle Relaxants: Therapeutic Uses
Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Myasthenia Gravis ll: Pathophysiology

